Smart radiation bullet targets Hard-to-Treat cancers
NCT ID NCT06710756
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 33 times
Summary
This study tests a new type of radiation therapy that specifically targets cancer cells with a protein called FAP. The treatment uses a radioactive substance (lead-212) attached to a molecule that seeks out FAP-positive tumors. The trial includes 112 adults with advanced pancreatic, gastric, esophageal, colorectal, ovarian, head and neck cancers, sarcoma, or mesothelioma who have not responded to standard treatments. The goal is to see if the treatment is safe and to find the best dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Biogenix
RECRUITINGMiami, Florida, 33165, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Nebraska Cancer Specialists
RECRUITINGOmaha, Nebraska, 68130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ohio State University
RECRUITINGColumbus, Ohio, 43221, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Saint Louis University
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Email: •••••@•••••
Contact
-
University of Kentucky
RECRUITINGLexington, Kentucky, 40536, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Miami
RECRUITINGMiami, Florida, 33125, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh Medical Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
A radioactive drug (lead-212 attached to a targeting molecule) that seeks out and delivers radiation to cancer cells with a specific marker (FAP).
What this could lead to
If successful, this could offer a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early-phase trial (Phase I/IIa) with a small number of participants, so the treatment may not prove effective or safe for wider use. Radiation side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.